Skip to main content
micro-community-banner
 
  • Saved

made a Post

The association between emotional dysregulation and REM sleep features in insomnia disorder.

Rapid Eye Movement (REM) sleep is involved in nightly emotional processing; therefore, its disruption might be associated with an impaired ability of emotional regulation during daytime. Accordingly, the aim of ..... see more

Source : https://europepmc.org/article/med/33190030

  • Saved

made a Post

Association between sleep structure and amnesic mild cognitive impairment in patients with insomnia disorder: a case-control study

To examine the association between sleep structure and amnesic mild cognitive impairment (aMCI) in patients with insomnia disorder. A total of 256 patients with insomnia disorder were diagnosed by neurologists, ..... see more

Source : https://jcsm.aasm.org/doi/abs/10.5664/jcsm.8804

  • Saved

made a Post

Automatic analysis of single-channel sleep EEG in a large spectrum of sleep disorders

To assess the performance of the single channel automatic sleep stage scoring (AS) software ASEEGA in adult patients suffering from various sleep disorders. Sleep recordings of 95 patients (38 women, ..... see more

Source : https://jcsm.aasm.org/doi/abs/10.5664/jcsm.8864

  • Saved

made a Post

Assessment of sleep quality in spouses of patients with restless legs syndrome; Are they also restless at night?

The aim of this study was to investigate the sleep quality of spouses of patients with restless legs syndrome (RLS). Total 49 spouses of patients with RLS (Group 1) and ..... see more

Source : https://link.springer.com/article/10.1007/s41105-020-00294-6

36-year-old male presents with insomnia

History of present illness: A 36-year-old male patient presents today for assistance with insomnia that began two years ago when he was ..... see more

  • Saved

made a Post

Enhanced Vigilance Stability during Daytime in Insomnia Disorder

Your access to the NCBI website at www.ncbi.nlm.nih.gov has been temporarily blocked due to a possible misuse/abuse situation involving your site. This is not an indication of a security issue ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33171860/

  • Saved

made a Post

The Impact of Sleep Disorders on Functional Recovery and Participation Following Stroke: A Systematic Review and Meta-Analysis

Your access to the NCBI website at www.ncbi.nlm.nih.gov has been temporarily blocked due to a possible misuse/abuse situation involving your site. This is not an indication of a security issue ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33153378/

  • Saved

made a Post

Assessment of sleep quality in spouses of patients with restless legs syndrome; Are they also restless at night?

The aim of this study was to investigate the sleep quality of spouses of patients with restless legs syndrome (RLS). Total 49 spouses of patients with RLS (Group 1) and ..... see more

Source : https://link.springer.com/article/10.1007/s41105-020-00294-6

ADD and Insomnia in Male Patient

A male patient, 30, came into the clinic complaining of being unable to fall asleep. He did not have a ..... see more

  • Saved

made a Post

Correlates of olfactory impairment in middle-aged non-diabetic Caucasian subjects with stage I-II obesity

This study evaluates among middle-aged subjects with obesity the prevalence of olfactory impairment (OI) with respect to normative values and its correlation with body composition, cognition, sleep quality, and inflammation. ..... see more

Source : https://link.springer.com/article/10.1007/s00405-020-06442-5

  • Saved

made a Post

Associations of Mental Health and Personal Preventive Measure Compliance With Exposure to COVID-19 Information During Work Resumption Following the COVID-19 Outbreak in China: Cross-Sectional Survey Study

Original Paper 1 Precision Medicine Center, Scientific Research Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China 2 Big Data Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, ..... see more

Source : https://www.jmir.org/2020/10/e22596/

  • Saved

DAYVIGO® (lemborexant) CIV

The Benefits of DAYVIGO

DAYVIGO may help adult patients with insomnia characterized by difficulties with sleep onset and/or sleep maintenance.1

Expand +

For more information about DAYVIGO, see full Prescribing Information.

INDICATION

DAYVIGO (lemborexant) is an orexin receptor antagonist indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

  • DAYVIGO is contraindicated in patients with narcolepsy.

WARNINGS AND PRECAUTIONS

  • Central Nervous System (CNS) Depressant Effects and Daytime Impairment:
    DAYVIGO can impair daytime wakefulness. CNS depressant effects may persist in some patients up to several days after discontinuing DAYVIGO. Prescribers should advise patients about the potential for next-day somnolence.

    Driving ability was impaired in some subjects taking DAYVIGO 10 mg. Risk of daytime impairment is increased if DAYVIGO is taken with less than a full night of sleep remaining or at a higher than recommended dose. If taken in these circumstances, patients should not drive or engage in activities requiring mental alertness.

    Use with other classes of CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. Dosage adjustments of DAYVIGO and concomitant CNS depressants may be necessary when administered together. Use of DAYVIGO with other insomnia drugs is not recommended. Patients should be advised not to consume alcohol in combination with DAYVIGO.

    Because DAYVIGO can cause drowsiness, patients, particularly the elderly, are at a higher risk of falls.

  • Sleep Paralysis, Hypnagogic/Hypnopompic Hallucinations, and Cataplexy-Like Symptoms:
    Sleep paralysis, an inability to move or speak for up to several minutes during sleep-wake transitions, hypnagogic/hypnopompic hallucinations, including vivid and disturbing perceptions can occur with DAYVIGO. Prescribers should explain these events to patients.

    Symptoms similar to mild cataplexy can occur with DAYVIGO and can include periods of leg weakness lasting from seconds to a few minutes, can occur either at night or during the day, and may not be associated with identified triggering event (e.g., laughter or surprise).

  • Complex Sleep Behaviors:
    Complex sleep behaviors, including sleep-walking, sleep-driving, and engaging in other activities while not fully awake (e.g., preparing and eating food, making phone calls, having sex), have been reported to occur with the use of hypnotics such as DAYVIGO. Events can occur in hypnotic-naïve and hypnotic-experienced persons. Patients usually do not remember these events. Complex sleep behaviors may occur following the first or any subsequent use of DAYVIGO, with or without the concomitant use of alcohol and other CNS depressants. Discontinue DAYVIGO immediately if a patient experiences a complex sleep behavior.

  • Patients with Compromised Respiratory Function:
    The effect of DAYVIGO on respiratory function should be considered for patients with compromised respiratory function. DAYVIGO has not been studied in patients with moderate to severe obstructive sleep apnea (OSA) or chronic obstructive pulmonary disease (COPD).

  • Worsening of Depression/Suicidal Ideation:
    Incidence of suicidal ideation or suicidal behavior, as assessed by questionnaire, was higher in patients receiving DAYVIGO than placebo (0.3% for DAYVIGO 10 mg, 0.4% for DAYVIGO 5 mg, and 0.2% for placebo). In primarily depressed patients treated with hypnotics, worsening of depression and suicidal thoughts and actions (including completed suicides) have been reported. Suicidal tendencies may be present in such patients and protective measures may be required. Intentional overdose is more common in this group of patients; therefore, the lowest number of tablets that is feasible should be prescribed at any one time. The emergence of any new behavioral sign or symptom of concern requires careful and immediate evaluation.

  • Need to Evaluate for Comorbid Diagnoses:
    Treatment of insomnia should be initiated only after careful evaluation of the patient. Re-evaluate for comorbid conditions if insomnia persists or worsens after 7 to 10 days of treatment. Worsening of insomnia or the emergence of new cognitive or behavioral abnormalities may be the result of an unrecognized underlying psychiatric or medical disorder and can emerge during the course of treatment with sleep-promoting drugs such as DAYVIGO.

ADVERSE REACTIONS

  • The most common adverse reaction (reported in 5% of patients treated with DAYVIGO and at least twice the rate of placebo) with DAYVIGO was somnolence (10% for DAYVIGO 10 mg, 7% for DAYVIGO 5 mg, 1% for placebo).

DRUG INTERACTIONS

  • CYP3A Inhibitors: The maximum recommended dose of DAYVIGO is 5 mg no more than once per night when co-administered with weak CYP3A inhibitors. Avoid concomitant use of DAYVIGO with strong or moderate CYP3A inhibitors.

  • CYP3A Inducers: Avoid concomitant use of DAYVIGO with moderate or strong CYP3A inducers.

USE IN SPECIFIC POPULATIONS

  • Pregnancy and Lactation: There is a pregnancy exposure registry that monitors pregnancy outcomes in women who are exposed to DAYVIGO during pregnancy. Healthcare providers are encouraged to register patients in the DAYVIGO pregnancy registry by calling 1-888-274-2378. There are no available data on DAYVIGO use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.

    There are no data on the presence of lemborexant in human milk, the effects on the breastfed infant, or the effects on milk production. Infants exposed to DAYVIGO through breastmilk should be monitored for excess sedation.

  • Geriatric Use: Exercise caution when using doses higher than 5 mg in patients ≥65 years old.

  • Renal Impairment: Patients with severe renal impairment may experience an increased risk of somnolence.

  • Hepatic Impairment: The maximum recommended dose of DAYVIGO is 5 mg in patients with moderate hepatic impairment. DAYVIGO is not recommended in patients with severe hepatic impairment. Patients with mild hepatic impairment may experience an increased risk of somnolence.

DRUG ABUSE AND DEPENDENCE

  • DAYVIGO is a Schedule IV-controlled substance.

  • Because individuals with a history of abuse or addiction to alcohol or other drugs may be at increased risk for abuse and addiction to DAYVIGO, follow such patients carefully.

Price disclosure information for prescribers available here.

Reference:
1. DAYVIGO (lemborexant) [Prescribing Information]. Woodcliff Lake, NJ: Eisai Inc.

DAYVIGO® is a registered trademark used by Eisai Inc. under license from Eisai R&D Management Co., Ltd.
© 2020 Eisai Inc. All rights reserved. DAYV-US2714 10/2020

  • Saved

made a Post

Peripheral Inflammasome Dysregulation in Patients with Chronic Insomnia

Your access to the NCBI website at www.ncbi.nlm.nih.gov has been temporarily blocked due to a possible misuse/abuse situation involving your site. This is not an indication of a security issue ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33076644/

  • Saved

made a Post

Optogenetic sleep enhancement improves fear-associated memory processing following trauma exposure in rats

Sleep disturbances are commonly found in trauma-exposed populations. Additionally, trauma exposure results in fear-associated memory impairments. Given the interactions of sleep with learning and memory, we hypothesized that increasing sleep ..... see more

Source : https://www.nature.com/articles/s41598-020-75237-9

  • Saved

made a Post

PTSD symptoms in healthcare workers facing the three coronavirus outbreaks: What can we expect after the COVID-19 pandemic

Your access to the NCBI website at www.ncbi.nlm.nih.gov has been temporarily blocked due to a possible misuse/abuse situation involving your site. This is not an indication of a security issue ..... see more

Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7370915/

College Student Experiencing Sleep Disorder

A 25-year-old grad student sought treatment for excessive daytime sleepiness. He has been experiencing this condition for at least three years and has noted ..... see more

  • Saved

made a Post

Sex differences in self-report anxiety and sleep quality during COVID-19 stay-at-home orders

COVID-19 and home isolation has impacted quality of life, but the perceived impact on anxiety and sleep remains equivocal. The purpose of this study was to assess the impact of ..... see more

Source : https://bsd.biomedcentral.com/articles/10.1186/s13293-020-00333-4

  • Saved

made a Post

Altered thalamic connectivity in insomnia disorder during wakefulness and sleep

Hongqiang Sun Corresponding Author E-mail address: sunhq@bjmu.edu.cn Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for ..... see more

Source : https://onlinelibrary.wiley.com/doi/full/10.1002/hbm.25221

  • Saved

made a Post

The role of rating scales in the diagnosis of postoperative insomnia

O.Yu. Boduliev Ukrainian Medical Stomatological Academy, Poltava, Ukraine Background. Sleep disorders can be considered as an integral expression of the perioperative stress response. Postoperative insomnia is one of the most ..... see more

Source : https://infusion-chemotherapy.com/index.php/journal/article/view/31

  • Saved

made a Post

Sleep Issues in Parkinson's Disease and Their Management

Parkinson's disease (PD) is an alpha-synucleinopathy that leads to prominent motor symptoms including tremor, bradykinesia, and postural instability. Nonmotor symptoms including autonomic, neurocognitive, psychiatric symptoms, and sleep disturbances are also ..... see more

Source : https://link.springer.com/article/10.1007/s13311-020-00938-y

  • Saved

made a Post

Sleep quality and sleep-disturbing factors of geriatric inpatients

To evaluate the change in sleep patterns and sleep quality in older patients during hospitalization. Sleep duration was shortened; however, sleep quality was not changed during hospitalization. Insomnia is associated ..... see more

Source : https://link.springer.com/article/10.1007/s41999-020-00400-4

  • Saved

made a Post

OSA in patients with head and neck cancer is associated with cancer size and oncologic outcome

Obstructive sleep apnea (OSA) is associated with severe daytime sleepiness and reduced quality of life. These symptoms are also present in patients with squamous cell carcinoma of the head and ..... see more

Source : https://link.springer.com/article/10.1007/s00405-020-06355-3

  • Saved

made a Post

OSA in patients with head and neck cancer is associated with cancer size and oncologic outcome

Obstructive sleep apnea (OSA) is associated with severe daytime sleepiness and reduced quality of life. These symptoms are also present in patients with squamous cell carcinoma of the head and ..... see more

Source : https://link.springer.com/article/10.1007/s00405-020-06355-3

  • Saved

made a Post

A prospective controlled study about sleep disorders in drug resistant epilepsy - PubMed

Self-reported confusional arousals, probable RBD and a high risk for sleep apnea occurred significantly more often in patients with drug resistant epilepsy. Sleep quality differed significantly between both groups. Whether ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/32987342/

Evaluation of sleep disorders, anxiety and depression in women with dysmenorrhea

The purpose of the study is to evaluate sleep disorders in dysmenorrhea patients and investigate the relationship between sleep disorders and anxiety and depression levels in these patients. This cross-sectional ..... see more

Source : https://link.springer.com/article/10.1007/s41105-020-00283-9

  • Saved

made a Post

Insomnia in adults with cystic fibrosis: strong association with anxiety/depression and impaired quality of life

Background: While sleep disruption is a common complaint among children with cystic fibrosis (CF), only a few studies have investigated insomnia in adults. The aim of this study was to ..... see more

Source : https://www.researchsquare.com/article/rs-74940/v1

  • Saved

made a Post

Altered long‐ and short‐range functional connectivity density associated with poor sleep quality in patients with chronic insomnia disorder: A resting‐state fMRI study

Fuqing Zhou Corresponding Author E-mail address: fq.chou@yahoo.com E-mail address: honghan_gong@sina.com https://orcid.org/0000-0002-0890-910X Department of Radiology, The First Affiliated Hospital, Nanchang University, Nanchang, China Neuroimaging Laboratory, Jiangxi Province Medical Imaging Research Institute, ..... see more

Source : https://onlinelibrary.wiley.com/doi/full/10.1002/brb3.1844

  • Saved

made a Post

Functional connectome fingerprint of sleep quality in insomnia patients: Individualized out-of-sample prediction using machine learning - Neuroimage Clin. - X-MOL

Insomnia disorder has been reclassified into short-term/acute and chronic subtypes based on recent etiological advances. However, understanding the similarities and differences in the neural mechanisms underlying the two subtypes and ..... see more

Source : https://www.x-mol.com/paper/1307738447463813120

  • Saved

made a Post

Shorter dream-stage sleep may be related to earlier death - Harvard Health Blog

Time and time again, adequate sleep has been shown to be critical to daily functioning and long-term health. Sleep serves numerous roles: recovering energy for the brain, clearing waste products, ..... see more

Source : https://www.health.harvard.edu/blog/shorter-dream-stage-sleep-may-be-related-to-earlier-death-2020091820932

  • Saved

made a Post

Sleep Disorders in Stroke: An Update on Management

Review | Hongxia Cai 1, Xiao-Ping Wang 1, *, Guo-Yuan Yang 2, * 1Department of Neurology, Tong-Ren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. 2 Med-X Research ..... see more

Source : https://www.aginganddisease.org/EN/abstract/abstract147989.shtml

  • Saved

DAYVIGO® (lemborexant) CIV

Brought to you by Eisai Inc.

For more information about DAYVIGO, see full Prescribing Information.
Price disclosure information for prescribers available here.

References:
1. DAYVIGO (lemborexant) [Prescribing Information]. Woodcliff Lake, NJ: Eisai Inc.
2. Data on file. ISE. Eisai Inc., Woodcliff Lake, NJ.

DAYV-US2669 September 2020

Expand +

For more information about DAYVIGO, see full Prescribing Information.

INDICATION

DAYVIGO (lemborexant) is an orexin receptor antagonist indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

  • DAYVIGO is contraindicated in patients with narcolepsy.

WARNINGS AND PRECAUTIONS

  • Central Nervous System (CNS) Depressant Effects and Daytime Impairment:
    DAYVIGO can impair daytime wakefulness. CNS depressant effects may persist in some patients up to several days after discontinuing DAYVIGO. Prescribers should advise patients about the potential for next-day somnolence.

    Driving ability was impaired in some subjects taking DAYVIGO 10 mg. Risk of daytime impairment is increased if DAYVIGO is taken with less than a full night of sleep remaining or at a higher than recommended dose. If taken in these circumstances, patients should not drive or engage in activities requiring mental alertness.

    Use with other classes of CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. Dosage adjustments of DAYVIGO and concomitant CNS depressants may be necessary when administered together. Use of DAYVIGO with other insomnia drugs is not recommended. Patients should be advised not to consume alcohol in combination with DAYVIGO.

    Because DAYVIGO can cause drowsiness, patients, particularly the elderly, are at a higher risk of falls.

  • Sleep Paralysis, Hypnagogic/Hypnopompic Hallucinations, and Cataplexy-Like Symptoms:
    Sleep paralysis, an inability to move or speak for up to several minutes during sleep-wake transitions, hypnagogic/hypnopompic hallucinations, including vivid and disturbing perceptions can occur with DAYVIGO. Prescribers should explain these events to patients.

    Symptoms similar to mild cataplexy can occur with DAYVIGO and can include periods of leg weakness lasting from seconds to a few minutes, can occur either at night or during the day, and may not be associated with identified triggering event (e.g., laughter or surprise).

  • Complex Sleep Behaviors:
    Complex sleep behaviors, including sleep-walking, sleep-driving, and engaging in other activities while not fully awake (e.g., preparing and eating food, making phone calls, having sex), have been reported to occur with the use of hypnotics such as DAYVIGO. Events can occur in hypnotic-naïve and hypnotic-experienced persons. Patients usually do not remember these events. Complex sleep behaviors may occur following the first or any subsequent use of DAYVIGO, with or without the concomitant use of alcohol and other CNS depressants. Discontinue DAYVIGO immediately if a patient experiences a complex sleep behavior.

  • Patients with Compromised Respiratory Function:
    The effect of DAYVIGO on respiratory function should be considered for patients with compromised respiratory function. DAYVIGO has not been studied in patients with moderate to severe obstructive sleep apnea (OSA) or chronic obstructive pulmonary disease (COPD).

  • Worsening of Depression/Suicidal Ideation:
    Incidence of suicidal ideation or suicidal behavior, as assessed by questionnaire, was higher in patients receiving DAYVIGO than placebo (0.3% for DAYVIGO 10 mg, 0.4% for DAYVIGO 5 mg, and 0.2% for placebo). In primarily depressed patients treated with hypnotics, worsening of depression and suicidal thoughts and actions (including completed suicides) have been reported. Suicidal tendencies may be present in such patients and protective measures may be required. Intentional overdose is more common in this group of patients; therefore, the lowest number of tablets that is feasible should be prescribed at any one time. The emergence of any new behavioral sign or symptom of concern requires careful and immediate evaluation.

  • Need to Evaluate for Comorbid Diagnoses:
    Treatment of insomnia should be initiated only after careful evaluation of the patient. Re-evaluate for comorbid conditions if insomnia persists or worsens after 7 to 10 days of treatment. Worsening of insomnia or the emergence of new cognitive or behavioral abnormalities may be the result of an unrecognized underlying psychiatric or medical disorder and can emerge during the course of treatment with sleep-promoting drugs such as DAYVIGO.

ADVERSE REACTIONS

  • The most common adverse reaction (reported in 5% of patients treated with DAYVIGO and at least twice the rate of placebo) with DAYVIGO was somnolence (10% for DAYVIGO 10 mg, 7% for DAYVIGO 5 mg, 1% for placebo).

DRUG INTERACTIONS

  • CYP3A Inhibitors: The maximum recommended dose of DAYVIGO is 5 mg no more than once per night when co-administered with weak CYP3A inhibitors. Avoid concomitant use of DAYVIGO with strong or moderate CYP3A inhibitors.

  • CYP3A Inducers: Avoid concomitant use of DAYVIGO with moderate or strong CYP3A inducers.

USE IN SPECIFIC POPULATIONS

  • Pregnancy and Lactation: There is a pregnancy exposure registry that monitors pregnancy outcomes in women who are exposed to DAYVIGO during pregnancy. Healthcare providers are encouraged to register patients in the DAYVIGO pregnancy registry by calling 1-888-274-2378. There are no available data on DAYVIGO use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.

    There are no data on the presence of lemborexant in human milk, the effects on the breastfed infant, or the effects on milk production. Infants exposed to DAYVIGO through breastmilk should be monitored for excess sedation.

  • Geriatric Use: Exercise caution when using doses higher than 5 mg in patients ≥65 years old.

  • Renal Impairment: Patients with severe renal impairment may experience an increased risk of somnolence.

  • Hepatic Impairment: The maximum recommended dose of DAYVIGO is 5 mg in patients with moderate hepatic impairment. DAYVIGO is not recommended in patients with severe hepatic impairment. Patients with mild hepatic impairment may experience an increased risk of somnolence.

DRUG ABUSE AND DEPENDENCE

  • DAYVIGO is a Schedule IV-controlled substance.

  • Because individuals with a history of abuse or addiction to alcohol or other drugs may be at increased risk for abuse and addiction to DAYVIGO, follow such patients carefully.

Price disclosure information for prescribers available here.

Reference:
1. DAYVIGO (lemborexant) [Prescribing Information]. Woodcliff Lake, NJ: Eisai Inc.

DAYVIGO® is a registered trademark used by Eisai Inc. under license from Eisai R&D Management Co., Ltd.
© 2020 Eisai Inc. All rights reserved. DAYV-US2669 09/2020

  • Saved

made a Post

Lemborexant in insomnia disorder: a profile of its use

Lemborexant (Dayvigo™), a dual orexin receptor antagonist, is an effective and well-tolerated treatment option for adults with insomnia characterized by difficulties with sleep onset and/or sleep maintenance. In phase 3 ..... see more

Source : https://link.springer.com/article/10.1007/s40267-020-00771-5

  • Saved

made a Post

Sleep disorders and risk of dementia in patients with new‐onset type 2 diabetes: A nationwide population‐based cohort study

This study examined the relationship between sleep disorders and the risk of dementia in patients with newly diagnosed type 2 diabetes. This study used the Korean Health Screening Cohort data ..... see more

Source : https://onlinelibrary.wiley.com/doi/abs/10.1111/1753-0407.13092

  • Saved

made a Post

The relationship between insomnia and trait anger and anger expression among adolescents

Corresponding Author E-mail address: nevin4083@yahoo.com E-mail address: fatma.sisman@marmara.edu.tr https://orcid.org/0000-0001-9543-6875 Department of Nursing, Faculty Health Sciences, Marmara University, Istanbul, Turkey Correspondence Fatma N. Sisman, PhD, RN, Marmara Universitesi, Basibuyuk Kampusu, Hemsirelik ..... see more

Source : https://onlinelibrary.wiley.com/doi/abs/10.1111/jcap.12294

  • Saved

made a Post

Validation of Oximetry for Diagnosing Obstructive Sleep Apnea in a Clinical Setting

A large epidemiological study using oximetry to analyze obstructive sleep apnea (OSA) and metabolic comorbidities was performed in Japan; however, reliability and validity of oximetry in the Japanese population remains ..... see more

Source : https://www.mdpi.com/2624-5175/2/3/27

  • Saved

made a Post

Psychological distress and sleep problems when people are under interpersonal isolation during an epidemic: A nationwide multicenter cross-sectional study - PubMed

doi: 10.1192/j.eurpsy.2020.78. 1 Department of Neurosurgery, SanBo Brain Hospital, Capital Medical University, Beijing, China. 2 Dalian Medical University, Dalian, China. 3 Department of Pediatric Hematology-Oncology, Dalian Municipal Women and Children's ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/32854786/

  • Saved

made a Post

Study finds irregular sleep patterns double the risk of cardiovascular disease in older adults

Variability in sleep duration and timing may represent new and independent heart disease risk factor. Older adults with irregular sleep patterns - meaning they have no regular bedtime and wakeup ..... see more

Source : https://www.nih.gov/news-events/news-releases/study-finds-irregular-sleep-patterns-double-risk-cardiovascular-disease-older-adults

  • Saved

made a Post

Selecting a pharmacotherapy regimen for patients with chronic insomnia

Chronic insomnia, whether it is primary or in combination with another medical or psychiatric disorder, is a prevalent condition associated with significant morbidity, reduced productivity, increased risk of accidents, and ..... see more

Source : https://www.tandfonline.com/doi/abs/10.1080/14656566.2020.1743265

  • Saved

made a Post

Objective rest-activity cycle analysis by actigraphy identifies isolated rapid eye movement sleep behavior disorder

Background and purpose Isolated rapid eye movement (REM) sleep behavior disorder (iRBD) is characterized by abnormal behaviours during REM sleep. Several studies showed that iRBD is a prodromal stag... see more

Source : https://onlinelibrary.wiley.com/doi/abs/10.1111/ene.14386?af=R

  • Saved

made a Post

Impact of COVID-19 lockdown on sleep quality in university students and administration staff

In Italy, lockdown due to COVID-19 health emergency started on March 10 and partially ended on May 3rd, 2020. There was a significant increase of psychological distress and symptoms of ..... see more

Source : https://link.springer.com/article/10.1007/s00415-020-10056-6

  • Saved

made a Post

Clinical Aspects in Sleep Disorders and Apnea

Thomas Penzel Ingo Fietze Sleep disorders are frequently reported complaints. Insomnia and hypersomnolence are symptoms often reported by patients and study participants. Sleep disorders with clinical consequences are not as ..... see more

Source : https://link.springer.com/referenceworkentry/10.1007/978-3-319-68864-0_41

  • Saved

made a Post

[Impact of sleep disorders on quality of life in epilepsy] - PubMed

Objective: To study the relationship between sleep disorder symptoms and health-related quality of life (HRQOL) in patients with epilepsy. Material and methods: Three groups of participants were included: patients with ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/32621464/

  • Saved

made a Post

Independent and combined associations of sleep duration and sleep quality with common physical and mental disorders: Results from a multi-ethnic population-based study

Sleep duration and sleep quality are often linked to increased risk of mortality and morbidity. However, national representative data on both sleep duration and sleep quality and their relationship with ..... see more

Source : https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0235816